Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer: A Phase 1b Clinical Trial
Sign Up to like & getrecommendations! Published in 2018 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2018.4475
Abstract: Importance The phosphatidylinositol 3-kinase (PI3K) pathway is frequently activated in patients with estrogen receptor–positive (ER+), endocrine therapy–resistant breast cancers. Objective To assess the maximum tolerated dose (MTD), safety, and activity of alpelisib, an oral, PI3K&agr;-specific… read more here.
Keywords: phase; plus fulvestrant; pik3ca altered; wild type ... See more keywords